# Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Canonical URL: https://biopharmsignal.com/news/INBX/inhibrx-reports-interim-phase-2-data-for-inbrx-106-in-first-line-hnscc-initial-results-demonstrate-potential-costimulatory-benefit-over-pd-1-monotherapy
Ticker: INBX
Company: Inhibrx
Source: Inhibrx
Published: 2026-05-11 12:00 EST
Original Source URL: https://inhibrx.investorroom.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-16 13:00 EST — [Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million](https://biopharmsignal.com/news/INBX/inhibrx-announces-amended-loan-agreement-with-oxford-finance-expanding-total-fac-d29cd85b) — Source: Inhibrx
- 2026-06-15 13:15 EST — [Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma](https://biopharmsignal.com/news/INBX/inhibrx-announces-u-s-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conve-d0380d86) — Source: Inhibrx
- 2026-05-14 20:02 EST — [Inhibrx Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/INBX/inhibrx-reports-first-quarter-2026-financial-results) — Source: Inhibrx
- 2026-05-11 12:00 EST — [Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy](https://biopharmsignal.com/news/INBX/inhibrx-reports-interim-phase-2-data-for-inbrx-106-in-first-line-hnscc-initial-results-demonstrate-potential-costimulatory-benefit-over-pd-1-monotherapy) — Source: Inhibrx
- 2026-05-08 20:00 EST — [Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC](https://biopharmsignal.com/news/INBX/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-inbrx-106-hexagon-study-in-first-line-hnscc) — Source: Inhibrx
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)